Pulse Biosciences Inc (PLSE)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $3.71B
Last updated: Nov 17, 2026 at 11:05 AM ET
Pulse Biosciences Inc (PLSE) Earnings: Report Dates and Results
Pulse Biosciences (PLSE) is expected to report earnings on Feb 17, 2027. In the quarter ended Sep 30, 2026, Pulse Biosciences reported EPS of -$0.32, above the -$0.35 estimate. It beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PLSE has an expected report date of Feb 17, 2027.
PLSE Earnings Call
The latest PLSE earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 31 quarters below that had an estimate, PLSE beat 13, missed 17 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $395000, up 359.3% from $86000 a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.32 | -$0.35 | N/A | +8.57% | Beat | N/A | 4 | 0 up, 1 down | Nov 5, 2026 | $395000 |
| Jun 30, 2026 | -$0.36 | -$0.31 | -$0.33 - -$0.24 | -16.13% | Miss | N/A | 2 | 0 up, 1 down | Aug 6, 2026 | $434000 |
| Mar 31, 2026 | -$0.24 | -$0.22 | -$0.22 - -$0.22 | -9.73% | Miss | N/A | 1 | 0 up, 0 down | May 4, 2026 | $401000 |
| Dec 31, 2025 | -$0.18 | -$0.21 | N/A | +14.29% | Beat | N/A | 1 | 1 up, 0 down | Feb 19, 2026 | $264000 |
| Sep 30, 2025 | -$0.29 | -$0.31 | -$0.31 - -$0.31 | +6.45% | Beat | N/A | 1 | 0 up, 0 down | Nov 5, 2025 | $86000 |
| Jun 30, 2025 | -$0.28 | -$0.26 | N/A | -7.69% | Miss | N/A | N/A | 0 up, 0 down | Aug 12, 2025 | N/A |
| Mar 31, 2025 | -$0.25 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 8, 2025 | N/A |
| Dec 31, 2024 | -$0.31 | -$0.24 | N/A | -30.17% | Miss | N/A | N/A | N/A | Mar 27, 2025 | $1.66M |
| Sep 30, 2024 | -$0.21 | -$0.24 | N/A | +13.50% | Beat | N/A | N/A | N/A | Oct 30, 2024 | N/A |
| Jun 30, 2024 | -$0.20 | -$0.20 | N/A | +0.45% | Beat | N/A | N/A | N/A | Aug 12, 2024 | N/A |
| Mar 31, 2024 | -$0.18 | -$0.24 | N/A | +25.00% | Beat | N/A | N/A | N/A | May 7, 2024 | N/A |
| Dec 31, 2023 | -$0.22 | -$0.24 | N/A | +9.71% | Beat | N/A | N/A | 0 up, 0 down | Mar 28, 2024 | $1.74M |
| Sep 30, 2023 | -$0.19 | -$0.22 | N/A | +13.64% | Beat | N/A | N/A | 0 up, 0 down | Nov 13, 2023 | N/A |
| Jun 30, 2023 | -$0.22 | -$0.24 | N/A | +8.33% | Beat | N/A | 1 | 0 up, 0 down | Aug 10, 2023 | N/A |
| Mar 31, 2023 | -$0.26 | -$0.22 | -$0.22 - -$0.22 | -18.18% | Miss | N/A | 1 | 0 up, 0 down | May 11, 2023 | N/A |
| Dec 31, 2022 | -$0.25 | -$0.24 | -$0.24 - -$0.24 | -4.17% | Miss | N/A | 1 | 0 up, 0 down | Mar 30, 2023 | N/A |
| Sep 30, 2022 | -$0.49 | -$0.45 | -$0.45 - -$0.45 | -8.89% | Miss | N/A | 1 | 0 up, 0 down | Nov 10, 2022 | N/A |
| Jun 30, 2022 | -$0.44 | -$0.40 | -$0.42 - -$0.37 | -10.00% | Miss | N/A | 3 | 0 up, 0 down | Aug 10, 2022 | $265000 |
| Mar 31, 2022 | -$0.58 | -$0.52 | -$0.56 - -$0.50 | -11.54% | Miss | N/A | 3 | 0 up, 0 down | May 11, 2022 | $444000 |
| Dec 31, 2021 | -$0.52 | -$0.51 | -$0.54 - -$0.49 | -1.96% | Miss | N/A | 3 | 0 up, 0 down | Mar 31, 2022 | $844000 |
| Sep 30, 2021 | -$0.48 | -$0.53 | -$0.54 - -$0.53 | +9.43% | Beat | N/A | 3 | N/A | Nov 15, 2021 | $574000 |
| Jun 30, 2021 | -$0.48 | -$0.52 | N/A | +7.69% | Beat | N/A | 3 | N/A | Aug 9, 2021 | N/A |
| Mar 31, 2021 | -$0.44 | -$0.49 | -$0.52 - -$0.47 | +10.20% | Beat | N/A | 2 | N/A | May 10, 2021 | N/A |
| Dec 31, 2020 | -$0.54 | -$0.45 | -$0.45 - -$0.45 | -20.00% | Miss | N/A | 1 | N/A | Feb 22, 2021 | N/A |
| Sep 30, 2020 | -$0.51 | -$0.44 | -$0.44 - -$0.44 | -15.91% | Miss | N/A | 1 | N/A | Nov 9, 2020 | N/A |
| Jun 30, 2020 | -$0.53 | -$0.50 | -$0.50 - -$0.50 | -6.00% | Miss | N/A | 1 | N/A | Aug 10, 2020 | N/A |
| Mar 31, 2020 | -$0.57 | -$0.47 | -$0.47 - -$0.47 | -21.28% | Miss | N/A | 1 | N/A | May 11, 2020 | $78000 |
| Dec 31, 2019 | -$0.66 | -$0.61 | -$0.61 - -$0.61 | -8.20% | Miss | N/A | 1 | N/A | Mar 16, 2020 | N/A |
| Sep 30, 2019 | -$0.57 | -$0.61 | -$0.61 - -$0.61 | +6.56% | Beat | N/A | 1 | N/A | Nov 7, 2019 | $218000 |
| Jun 30, 2019 | -$0.55 | -$0.51 | -$0.51 - -$0.51 | -7.84% | Miss | N/A | 1 | N/A | Aug 8, 2019 | $290000 |
| Mar 31, 2019 | -$0.49 | -$0.44 | -$0.44 - -$0.44 | -11.36% | Miss | N/A | 1 | N/A | Apr 30, 2019 | $332000 |
| Dec 31, 2018 | -$0.51 | -$0.51 | N/A | 0.00% | In line | N/A | N/A | N/A | Mar 14, 2019 | $135000 |
| Sep 30, 2018 | -$0.64 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Oct 30, 2018 | $118000 |
| Jun 30, 2018 | -$0.54 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jul 31, 2018 | $137000 |
| Mar 31, 2018 | -$0.51 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 8, 2018 | $56000 |
| Dec 31, 2017 | -$0.52 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 16, 2018 | $128000 |
| Sep 30, 2017 | -$0.52 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 7, 2017 | $39000 |
| Jun 30, 2017 | -$0.43 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jul 27, 2017 | $41000 |
| Mar 31, 2017 | -$0.23 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 4, 2017 | $39000 |
| Dec 31, 2016 | -$0.21 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 14, 2017 | $34000 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.00, after -$0.90 the year before. It was -$0.65 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.00 | N/A |
| Dec 31, 2024 | -$0.90 | N/A |
| Dec 31, 2023 | -$0.89 | N/A |
| Dec 31, 2022 | -$1.76 | N/A |
| Dec 31, 2021 | -$1.92 | N/A |
| Dec 31, 2020 | -$2.15 | N/A |
| Dec 31, 2019 | -$2.27 | N/A |
| Dec 31, 2018 | -$2.20 | N/A |
| Dec 31, 2017 | -$1.70 | N/A |
| Dec 31, 2016 | -$0.65 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,700 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 9,698 | 10 | |
| 2026Q2 | Jun 30, 2026 | 8,201 | 9 | |
| 2026Q1 | Mar 31, 2026 | 5,649 | 6 | |
| 2025Q4 | Dec 31, 2025 | 6,509 | 9 | |
| 2025Q3 | Sep 30, 2025 | 3,861 | 5 | |
| 2025Q2 | Jun 30, 2025 | 4,556 | 6 | |
| 2025Q1 | Mar 31, 2025 | 2,775 | 4 | |
| 2024Q4 | Dec 31, 2024 | 3,877 | 4 |
2026Q3 Earnings Call
Opening remarks
Tripp Taylor Investor Relations Thank you, operator. Before we begin, I'd like to inform you that comments and responses to your questions during today's call reflect management's views as of today, November 5, 2026, only and will include forward-looking statements and opinion statements, including predictions, estimates, plans, expectations, and other similar information. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are more fully described in our press release issued today and in our filings with the U.S. Securities and Exchange Commission. Our SEC filings can be found on our website or on the SEC's website. Investors are cautioned not to place undue reliance on forward-looking statements. We disclaim any obligation to update or revise these forward-looking statements. We will also discuss certain non-GAAP financial measures. Disclosures regarding these non-GAAP financial measures, including reconciliations with the most comparable GAAP measures, can be found in the press release. Please note that this conference call will be available for audio replay on our website at pulsebiosciences.com in the News and Events section on our Investor Relations page. With that, I would now like to turn the call over to Co-Chair of the Board and Chief Executive Officer, Paul LaViolette.
Paul LaViolette Co-Chair of the Board and CEO Thank you, Tripp. Good afternoon, and thank you, everyone, for joining us today to discuss our third quarter 2026 results and business progress. The team at Pulse Biosciences delivered a strong quarter, and we are looking forward to creating continued momentum in Q4 and into 2027. I will begin by describing the technology at the core of everything we do at Pulse Biosciences: our proprietary Nanosecond Pulse Field Ablation energy, or nsPFA, technology. nsPFA produces a fundamentally unique form of non-thermal ablation energy with a differentiated mechanism of action to treat cells. Because our pulses last only billionths of a second, there is virtually no energy deposition that converts to heat and almost no rise in the temperature of the tissue being treated or of adjacent areas. The unique nsPFA energy acts on the membranes of the structures inside the cell, causing the cell to undergo regulated cell death without unwanted inflammatory responses. In addition, this energy is delivered very efficiently. High-efficiency energy delivery allows our catheter system to produce cardiac ablation lesions in tissue that are larger, deeper, and more consistent than lesions created with early-generation PFA systems. The combination of highly efficient lesion production and a very effective ablation mechanism of action results in a non-thermal ablation with exceptional procedural workflow efficiency, very reliable lesion formation, and minimized risk of collateral tissue injury.
Frequently Asked Questions About PLSE
When is Pulse Biosciences's next earnings date?
Pulse Biosciences's next earnings report is expected for Feb 17, 2027.
Did PLSE beat earnings estimates last quarter?
Yes. Pulse Biosciences reported EPS of -$0.32 for the quarter ended Sep 30, 2026, above the -$0.35 estimate, a 8.57% surprise.
What EPS do analysts expect from PLSE next quarter?
The consensus EPS estimate for Pulse Biosciences for the quarter ending Dec 31, 2026 is -$0.37 from 8 analysts, with estimates from -$0.38 to -$0.37.
How often does PLSE beat earnings estimates?
Pulse Biosciences beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate, with an average surprise of -2.61%.
PLSE pages: Overview, Earnings, Forecast, Financials, Competitors